Introduction {#section6-1352458517698250}
============

Although clinical trials are the gold standard for obtaining rigorous clinical data, their focus on individual agents and their relatively short duration limit their value for answering critical questions related to the evolution of multiple sclerosis (MS), particularly as it transitions into the progressive phase. For most individuals with MS, the progressive course can take more than 10 years to develop and then evolves over many decades, thus much longer follow-up is needed. Registries and cohorts that follow patients over a long time in a real-world environment have the potential to identify factors contributing to disability progression, individuals who are likely to benefit from early treatment, and the most effective treatment approach. Furthermore, if detailed physician- and patient-reported data are accompanied by both magnetic resonance imaging (MRI) of the central nervous system (CNS) and biological samples, significant insight into the pathophysiology of progressive MS could be achieved, which would likely accelerate development of disease-modifying treatments.

Substantial investments are being made in a growing number of efforts collecting detailed phenotypic and genotypic data from groups of MS patients. Improved awareness of existing and planned cohorts and registries is needed to better coordinate these efforts and maximize the impact of the limited resources available to support them. Greater coordination will reduce duplication, enhance scientific credibility, and sharpen the focus on the most critical unanswered questions in MS. The purpose of this report is to provide a landscape of the current and planned longitudinal MS patient data collection efforts and propose recommendations for increasing their impact.

Landscape {#section7-1352458517698250}
=========

MS cohort and registry studies have provided fundamental information about MS prevalence and incidence, rates of disability progression, and life expectancy. More contemporary studies of correlations between outcome and demographic/clinical data,^[@bibr1-1352458517698250]^ the presence or absence of associations between exposure and MS risk,^[@bibr2-1352458517698250][@bibr3-1352458517698250]--[@bibr4-1352458517698250]^ disease-modifying therapy use and disability progression,^[@bibr5-1352458517698250]^ and a proposed algorithm defining secondary progressive MS^[@bibr6-1352458517698250]^ have added to our understanding of the natural history of MS.

A growing number of data collection efforts are underway ([Table 1](#table1-1352458517698250){ref-type="table"}). These efforts differ in their genesis, recruitment criteria, types and frequencies of data collected (clinical, patient-reported outcomes, biospecimens, imaging), catchment area, and duration of follow-up, among others.

###### 

Sample of major MS cohorts and registries underway.

![](10.1177_1352458517698250-table1)

  Cohort                                                                                       URL                                                                                                                                                        Primary contact-email                            Key attributes                                                                                                                                                                     Open Access                                                      No. of active participants/registrants                                                                                                    Enrollment dates                                                          Geographic catchment                                            CIS/relapsing/progressive                                             Plasma/serum/cells                                  DNA/RNA                                             MRI imaging data/frequency                                                                                                                  Physician-reported outcomes   Patient-reported outcomes
  -------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------- --------------------------------------------------------------- --------------------------------------------------------------------- --------------------------------------------------- --------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------- ----------------------------------
  Accelerated Cure Project                                                                     [www.acceleratedcure.org](http://www.acceleratedcure.org)                                                                                                  <sloud@acceleratedcure.org>                      High-quality biospecimens with extensive associated data                                                                                                                           Yes                                                              3220 total (1787 MS + controls)                                                                                                           2006--2012                                                                10 MS clinics in the United States                              Yes/yes/yes                                                           Yes/yes/yes                                         Yes/yes                                             No images, only descriptors                                                                                                                 Yes                           Yes
  British Columbia MS Database                                                                 <http://epims.med.ubc.ca/>                                                                                                                                 <helen.tremlett@ubc.ca>                          Longitudinal, clinical, linkable to population-based health administrative data                                                                                                    Upon request                                                     Total (1980--present): 10,000+                                                                                                            August/1980--present                                                      British Columbia, Canada                                        Limited/yes/yes                                                       Study-specific collection only                      Study-specific collection only                      Study-specific collection only                                                                                                              Yes                           Study-specific collection only
  Centre d'Esclerosi Múltiple de Catalunya (Cemcat)                                            <https://www.cem-cat.org/>                                                                                                                                 <xavier.montalban@cem-cat.org>                   Longitudinal deep phenotyping                                                                                                                                                      No                                                               2500                                                                                                                                      1995--present                                                             Catalonia, Spain                                                Yes/yes/no                                                            Yes/yes/yes                                         Yes/yes                                             Baseline, year 1, every 5 years                                                                                                             Yes                           No
  Cleveland Clinic Knowledge Program                                                                                                                                                                                                                      <COHENJ@ccf.org>                                 Longitudinal follow-up of clinic population                                                                                                                                        No                                                               4900                                                                                                                                      2007--present                                                             Ohio/Midwest, also national and international                   Yes/yes/yes                                                           No/no/no                                            No/no                                               Yes, ad hoc                                                                                                                                 Yes                           Yes
  Comprehensive Longitudinal Investigation of MS (CLIMB)                                       <http://www.climbstudy.org>                                                                                                                                <tchitnis@rics.bwh.harvard.edu>                  Longitudinal deep phenotyping                                                                                                                                                      Upon request                                                     2100                                                                                                                                      February 2000--present                                                    Boston/greater New England                                      Yes/yes/yes                                                           Yes/yes/yes                                         Yes/derived                                         Yes, annual                                                                                                                                 Yes                           Subset
  Danish MS Registry (DMSR)                                                                    <http://www.ms-research.dk/>                                                                                                                               <melinda_magyari@dadlnet.dk>                     Longitudinal, nationwide, population based                                                                                                                                         Yes by application                                               25,000                                                                                                                                    Since 1956                                                                Denmark                                                         Yes/yes/yes                                                           No/no/no only CSF                                   No                                                  No                                                                                                                                          Yes                           Yes
  iConquerMS                                                                                   <https://www.iconquerms.org/for-researchers>                                                                                                               <iConquerMS@acceleratedcure.org>                 Patient-powered research; longitudinal; patient-reported outcomes                                                                                                                  Yes                                                              3200 and growing                                                                                                                          February 2015--present                                                    Primarily US-based with no geographic limitations (worldwide)   Yes/yes/yes                                                           Not yet                                             DNA collection piloted; expansion with funding      No                                                                                                                                          No, in development            Yes
  Italian MS Register                                                                                                                                                                                                                                     <registroitalianosm@aism.it>                     Longitudinal prospective cohort                                                                                                                                                    Upon request                                                     36,200                                                                                                                                    2014--present                                                             Italy                                                           Yes/yes/yes                                                           No/no/no                                            No                                                  Yes/annual                                                                                                                                  Yes                           No
  Kaiser Permanente, SoCal                                                                                                                                                                                                                                <Annette.M.Langer-Gould@kp.org>                  Multi-racial/ethnic population representative of geographic region. Incident cases with complete health record; matched controls for \>600 participants in the MS Sunshine Study   No                                                               \~1500 total; MS Sunshine Study \>600 incident cases with detailed environmental exposures, genetic information, and stored sera/plasma   January 2008--present entire incident cohort; subgroup 2011--2015         Southern California                                             Yes/yes/yes (total cohort and MS Sunshine study; also includes NMO)   Yes/yes/no from MS Sunshine Study                   Yes/yes for MS Sunshine Study                       Yes, standard of care, all cases                                                                                                            Yes                           Subgroup
  MS Clinic Database and Registry, Health Sciences Centre, Winnipeg                                                                                                                                                                                       <rmarrie@exchange.hsc.mb.ca>                     Clinical registry for recruitment for research studies; core data can be used for record review/linkage studies                                                                    No                                                               2061                                                                                                                                      April 2011--present                                                       Manitoba, Canada/northwestern Ontario                           Yes/yes/yes                                                           No/no/no                                            No/no                                               MRI reports could be reviewed/clinical judgment                                                                                             Yes                           Yes
  MS genetics-expression, proteomics, imaging clinical (EPIC)                                  <http://msepicstudy.com/>                                                                                                                                  <hausers@neurology.ucsf.edu>                     Longitudinal deep phenotyping with 85% at 10+ years                                                                                                                                Upon request                                                     530                                                                                                                                       June 2004--present                                                        San Francisco, CA                                               Yes/yes/yes                                                           Yes/yes/yes                                         Yes/yes                                             Yes, annual                                                                                                                                 Yes                           Yes
  MSBASE                                                                                       <https://www.msbase.org>                                                                                                                                   <info@msbase.org>                                Longitudinal, multinational. Min. dataset = demographics, EDSS, relapses, DMT exposure, diagnostic test info                                                                       Access within collaborative group                                42,248 (as of 11 October 2016)                                                                                                            January 2004--present                                                     Global---38 participating countries                             Yes/yes/yes NMO                                                       Yes/yes/no in subsets                               Yes/no in subsets                                   No images, only descriptors                                                                                                                 Yes                           Subset
  NARCRMS                                                                                      <http://narcrms.org/>                                                                                                                                      <krammohan@med.miami.edu>, <dj9d@virginia.edu>   Longitudinal registry, clinician collected, soon to include MRI. Eventual interface with NARCOMS                                                                                   Yes                                                              Currently 15, but goal of 1000 in 5 years                                                                                                 June 2016 to present                                                      North America                                                   Yes/yes/yes                                                           Eventually, RFP in development                      No/no                                               Yes, annual                                                                                                                                 Yes                           Yes
  North American Research Committee on MS (NARCOMS)                                            <http://narcoms.org/>                                                                                                                                      <MSregistry@narcoms.org>                         Longitudinal self-reporting                                                                                                                                                        No                                                               11,000                                                                                                                                    1996--present                                                             Global, mainly the United States                                Yes/yes/yes                                                           No/no/no                                            No/no                                               No                                                                                                                                          No                            Yes
  Norwegian MS Registry & Biobank                                                              <https://helse-bergen.no/avdelinger/nevroklinikken/nevrologisk-avdeling/nasjonal-kompetansetjeneste-for-multippel-sklerose/norsk-ms-register-og-biobank>   <kjell-morten.myhr@helse-bergen.no>              Longitudinal follow-up phenotyping                                                                                                                                                 By application                                                   ca 8000                                                                                                                                   2001                                                                      Norway                                                          No/yes/yes                                                            No/yes/no                                           Yes/no                                              Yes, prospectively for 2016                                                                                                                 Yes                           Yes from 2017
  NY State MS Consortium                                                                       <http://www.nysmsc.org/nyregistry.asp>                                                                                                                     <BWeinstock-Guttman@KaleidaHealth.org>           Longitudinal data collection, historical cohort with no DMT use, patient-reported and clinical outcomes                                                                            Yes for affiliated centers                                       9650 enrolled/18,000 follow-ups                                                                                                           1996--present                                                             New York, some Northwestern Pennsylvania                        Yes/yes/yes                                                           Subset                                              Subset                                              Subset                                                                                                                                      Yes                           Yes
  OFSEP (Observatoire Français de la Sclérose en Plaques)                                      [www.ofsep.org](http://www.ofsep.org)                                                                                                                      <sandra.vukusic@chu-lyon.fr>                     Longitudinal clinical and MRI follow-up of French MS patients                                                                                                                      Yes                                                              58,000                                                                                                                                    2011 (but many local databases using the EDMUS software started before)   France                                                          Yes/yes/yes (+RIS and NMOSD)                                          Yes/yes/yes only in subgroups                       Yes/yes only in subgroups                           Yes, standardized acquisition, frequency according to local prescription                                                                    Yes                           No, in progress
  OPTIMISE                                                                                     <http://www.optimise-ms.org/>                                                                                                                              <p.matthews@imperial.ac.uk>                      Clinical data entry portal/database allows DICOM image upload with data management option in transMART platform                                                                    Yes                                                              1000 and growing                                                                                                                          Retrospective--present                                                    UK                                                              Not formally audited, all types                                       No/no/no but intended with future accrual           Limited transcriptomics                             Partial                                                                                                                                     Yes                           Wikihealth tool being added 2017
  PROMOPRO-MS                                                                                                                                                                                                                                             <giampaolo.brichetto@aism.it>                    Longitudinal, population-based, collected every 4 months, demographic, disease course, onset, treatments, physician-reported and patient-reported outcomes                         For research, by application                                     2000 and growing                                                                                                                          Longitudinal every 4 months from 2014                                     Italy                                                           No/yes/yes                                                            No/no/no                                            No/no                                               No, but intended with future integration with Italian NeuroImaging Network Initiative                                                       Yes                           Yes
  SMSC (Swiss MS Cohort)                                                                       <https://smsc.rodano.ch/>                                                                                                                                  <jens.kuhle@usb.ch> <claudio.gobbi@eoc.ch>       Prospective, observational, standardized demographic, clinical, MRI data and biospecimens, focus on newer disease-modifying drugs                                                  No, open for nested projects with a member of Scientific Board   1040/1102                                                                                                                                 June 2012--present                                                        7 Swiss MS Centers                                              Yes/yes/yes                                                           Yes/yes/yes selection                               Yes/no                                              Yes, annual                                                                                                                                 Yes                           No
  Sonya Slifka Longitudinal Multiple Sclerosis Study                                                                                                                                                                                                      <sminden@partners.org>                           Longitudinal, population-based, collected every 6--12 months, demographic, disease, health care use, costs, QOL; some on care providers, biospecimens for 150 newly dx             Yes with permission                                              4634                                                                                                                                      2000--2010                                                                United States                                                   No/yes/yes                                                            Yes/yes/no for subset                               Yes/yes for subset                                  No                                                                                                                                          No                            Yes
  SUMMIT                                                                                       [www.summit.org](http://www.summit.org)                                                                                                                    <summit@partners.org>                            Longitudinal deep phenotyping; enriching with newly dx, rx naive cohort                                                                                                            Yes                                                              1028                                                                                                                                      2000--present                                                             Boston/greater New England and greater San Francisco area       Yes/yes/yes                                                           Yes/yes/yes                                         Yes/yes                                             Yes, annual                                                                                                                                 Yes                           Yes
  Swedish MS Registry                                                                          <http://www.neuroreg.se/en.html/multiple-sclerosis-research>                                                                                               <Jan.hillert@ki.se>                              Longitudinal data on \>80% of the prevalent patient population, mean 6 years follow-up                                                                                             For research, by application                                     15,974 at 61 centers                                                                                                                      1995--present +1000 patients annually                                     Sweden                                                          Some/yes/yes                                                          In separate overlapping projects, 10,000 patients   In separate overlapping projects, 10,000 patients   High level info on \#lesions and \#Gd+ and \#new lesions or MS-indicative yes/no on 32,000 scores, that is, 2--3 per contributing patient   Yes                           Yes
  US Network of Pediatric MS Centers: Pediatric MS and other Demyelinating Diseases Database   <http://usnpmsc.org/>                                                                                                                                      <charlie.casper@hsc.utah.edu>                    Pediatric, longitudinal                                                                                                                                                            No                                                               1700                                                                                                                                      May 2011--present                                                         USA (participating centers)                                     Yes/yes/no                                                            No/no/no                                            No/no                                               Yes, as clinically ordered                                                                                                                  Yes                           No
  Veterans Health Administration MS National Data Repository                                   <http://www.va.gov/MS/index.asp>                                                                                                                           <Steven.Leipertz@va.gov>                         United States VHA Medical Records                                                                                                                                                  VHA Personnel and Affiliated                                     50,000                                                                                                                                    October 1998--present                                                     United States                                                   No/yes/yes                                                            No/no/no                                            No                                                  No                                                                                                                                          No                            No

MS: multiple sclerosis; CIS: clinically isolated syndrome; MRI: magnetic resonance imaging; CSF: cerebrospinal fluid; NMO: neuromyelitis optica; EDSS: Expanded Disability Status Scale; DMT: disease-modifying drug therapy; QOL: quality of life; RFP: Request for Proposals; NMOSD: Neuromyelitis Optica Spectrum Disorder; RIS: Radiologically Isolated Syndrome; VHA: Veterans Health Administration.

This list of MS cohort studies and registries is not exhaustive, and additional cohorts are under development.

The Swedish MS Registry (EIMS) is an example of a clinical data set that has contributed to our understanding of the impact of disease-modifying therapy. The effort has enrolled approximately 80% of patients with MS in Sweden. Due to the use of a national personal ID in Sweden, data can be linked with other Swedish databases to investigate associations between MS and factors such as employment-related factors, co-morbidities, and other epidemiological factors. Similarly, the Danish Multiple Sclerosis Registry (DMSR) has enrolled nearly all patients with MS in Denmark and has advanced the understanding of MS epidemiology.

MSBase is a physician-driven observational registry that is based in Australia and has recruited more than 42,000 participants from 38 countries. Although this collection does not include biospecimens or imaging data, its large size and broad catchment area position it to address critical questions concerning the impact of disease-modifying treatment on the natural history of MS.

Other cohorts have been prospectively designed primarily for research purposes. The Expression, Proteomics, Imaging and Clinical (EPIC) study, which is based at the University of California, San Francisco, is an observational cohort of over 500 people with MS who have been carefully studied since 2004. The Comprehensive Longitudinal Investigation of Multiple Sclerosis (CLIMB) is a large-scale, long-term study of about 1500 MS patients based at Harvard's Brigham and Women's Hospital. Recently, these two groups have combined efforts to form the Serially Unified Multi-center Multiple Sclerosis Investigation (SUMMIT) with the purpose of building an open platform to elucidate risk factors that affect disease progression. The New York State MS Consortium is another research effort that collects numerous types of data including patient-reported outcomes, quality of life measures, co-morbidities, insurance information, and disease-modifying therapy use, among others.

The North American Research Committee on MS (NARCOMS) and iConquerMS are voluntary patient-driven registries that collect data from MS patients about treatments, quality of life, and other factors related to living with MS.

Strengths and limitations of existing cohorts {#section8-1352458517698250}
=============================================

Existing cohorts have amassed large collections of data, and several have also established accompanying biospecimen repositories. Several cohorts are working toward standardization of data and the methods for biospecimen, imaging, and data collection.^[@bibr7-1352458517698250]^ Others are working toward creating standardized imaging protocols. Some registries are able to link to other databases (i.e. payor databases), which should enhance their ability to advance knowledge of the natural history of MS and address critical questions related to response to therapy and disability progression.

Many (but not all) efforts have been designed without a specific hypothesis and participant selection criteria. This "convenience cohort" approach allows the flexibility to ask different questions, but is limited by the unknown generalizability of the observations and conclusions. In addition, harmonizing data from different cohorts is often difficult due to the use of different data elements as well as incompatible platforms and standards (often developed "in house"). Changes in technology can also make comparisons challenging. Many cohorts are not readily accessible to other qualified investigators. Inconsistencies can result from different and evolving criteria used for diagnosing and defining MS subtypes, time to an event such as progressive disease, follow-up times, terminology, data collection methods, and physician perceptions and opinions. Unlike clinical trials, randomization is not possible, which introduces a risk for biases and confounders that can make interpretation of the results challenging. Cohorts that rely on patient-reported outcomes may also contain recall and referral bias.

Recommendations {#section9-1352458517698250}
===============

In February 2016, the US National Institute of Neurological Disorders and Stroke (NINDS) and the National Multiple Sclerosis Society convened a workshop that included over 50 thought leaders from around the world to evaluate how current and future MS cohorts might be better leveraged to answer urgent questions about progressive MS. The attendees included experts with academic, industry, and funders perspectives that developed the following recommendations.

Recommendation 1: create a federated network of cohorts {#section10-1352458517698250}
-------------------------------------------------------

The landscape analysis revealed a significant number of largely uncoordinated parallel efforts. The participants recommended that strategic oversight and direction would greatly streamline and leverage existing and future efforts. This could be accomplished by creating a federated network of cohorts and engaging in regular activities that could be coordinated by the NINDS, industry, and advocacy organizations like the National MS Society. The first steps by this network should be to prioritize research questions and develop a data sharing model.

Recommendation 2: standardize data collection and management {#section11-1352458517698250}
------------------------------------------------------------

Standardizing the collection and management of large data sets would greatly enhance the ability to share data and perform meta-analyses with aggregated data. The NINDS has developed common data elements for MS (<https://www.commondataelements.ninds.nih.gov/MS.aspx#tab=Data_Standards>) and recommends that MS cohorts incorporate this standard. The data standards established by the Clinical Data Inter-change Standards Consortium (CDISC) for MS (<http://www.cdisc.org/standards/therapeutic-areas/multiple-sclerosis>) would also increase the likelihood that data sets could be confederated and used to answer clinically relevant questions in progressive MS. Additional standardization will likely be needed.

Recommendation 3: identify and prioritize research questions {#section12-1352458517698250}
------------------------------------------------------------

Many cohorts were not designed to answer specific research questions; nonetheless, they should be mined to determine whether they can reveal significant insights into the natural history or pathogenesis of progressive MS or generate new hypotheses. Prioritizing research questions and focusing resources on high-priority research would likely accelerate progress and better leverage limited resources. Meeting participants identified several high-priority research topics including: (1) developing ways to measure progression, (2) developing proof-of-concept outcome measures, and (3) identifying prognostic factors. The participants recommended that meetings with a broader representation of stakeholders including patients be held to establish a consensus on the most critical research questions.

Recommendation 4: encourage collection of physician- and patient-reported outcomes {#section13-1352458517698250}
----------------------------------------------------------------------------------

Patient- and physician-reported data should be integrated to provide a more complete picture of living with MS. Patient-reported outcomes are likely to better capture patient experiences with MS including psychosocial experiences, bladder/bowel/vision problems, employment, cognitive disability, quality of life, fatigue, and pain. Information from private practice is currently not being captured, but could also provide valuable additional data.

Recommendation 5: encourage technological innovation {#section14-1352458517698250}
----------------------------------------------------

Researchers should continue to utilize new technologies such as electronic health records and data collection methods. The utility of these approaches will be greatly enhanced by the creation of a minimum set of clinical and imaging standards to be used in all MS interactions. Likewise, investigators should incorporate guidelines for biospecimen collection,^[@bibr7-1352458517698250]^ and centralization of these repositories should be encouraged.

Recommendation 6: develop a universal informed consent process {#section15-1352458517698250}
--------------------------------------------------------------

Patient privacy and associated laws, including Health Insurance Portability and Accountability Act (HIPAA) in the United States, vary across countries, and consent forms should be developed to allow sharing of data with other countries. Restrictive consent forms can hamper research, but overly broad consent may make obtaining approval from local institutional review boards difficult.

Recommendation 7: provide sustainable funding {#section16-1352458517698250}
---------------------------------------------

Cohorts are largely funded by grants with terms limited to 2--5 years. The most important unanswered questions in progressive MS will require following cohorts of patients for 10 years or longer, and thus, more sustained funding will be required. Better coordination and less duplication of data collection efforts should optimize the use of limited resources and allow for more sustained investments.

Conclusion {#section17-1352458517698250}
==========

Despite significant investments in MS cohort studies, major gaps in our understanding of the natural history of MS progression remain. Better coordination, increased leveraging of evolving technology, a focus on the most important unanswered questions, improved access, and more sustained funding are key requirements for closing the gaps in our understanding of progressive MS. This knowledge will likely accelerate the development of effective therapies for progressive MS.
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